| Поле DC | Значение | Язык |
|---|
| dc.contributor.author | Peresypkina, A. A. | - |
| dc.contributor.author | Dolzhikov, A. A. | - |
| dc.contributor.author | Gubareva, V. O. | - |
| dc.contributor.author | Levkova, E. A. | - |
| dc.contributor.author | Shabelnikova, A. S. | - |
| dc.date.accessioned | 2022-05-04T16:35:17Z | - |
| dc.date.available | 2022-05-04T16:35:17Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | The development of hypertensive neuroretinopathy model on wistar rats / A. A. Peresypkina [et al.] // Research result. Pharmacology and clinical pharmacology. - 2017. - Vol. 3, № 1.- P. 18-31. - Doi: 10.18413/2500-235X-2017-3-1-18-31. - Refer.: p. 30-31. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46596 | - |
| dc.description.abstract | A model of hypertensive neuroretinopathy was developed on Wistar line rats with administration of non-selective NO-synthase blocker N-nitro-L-arginine methyl ester (L-NAME) in a dose 12.5 mg/kg within 28 days on the background of single increased intraocular pressure (IOP) to 110 mmHg. As a result of the interim evaluation of pathology simulation mode the most optimal was a model of hypertensive neuroretinopathy with 5-minute increased IOP at day 26 of the experiment on the background of L-NAME for further study of neuroretinoprotective properties of pharmacological agents | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | hypertensive neuroretinopathy | ru |
| dc.subject | ophthalmoscopy | ru |
| dc.subject | laser Doppler flowmetry | ru |
| dc.subject | electroretinography | ru |
| dc.subject | experiments | ru |
| dc.title | The development of hypertensive neuroretinopathy model on wistar rats | ru |
| dc.type | Article | ru |
| Располагается в коллекциях: | Vol. 3, № 1
|
